Our Mission
To discover, develop and deliver innovative skincare products that help patients prevail over serious skin diseases, and improves the quality of their life.
Our Commitment
We commit to scientific excellence and investment in research and development to provide innovative, high-quality products that address the unmet needs of people with skin problems. We apply scientific rigor to produce clinical and economic benefit through products that improve peoples’ lives.
Our Company
Exquis LLC is a technology-based skincare company established in 2010 by founder, Dr. Kalidas Kale. The company is located 45 miles north of New York City in Harriman, NY. (http://www.ExquisSkincare.com). Exquis manufactures and sells unique, high end beauty and skincare products (Made in USA) that effectively treat eczema, acne, hyper pigmentation, mild psoriasis, while luxuriously hydrating and nourishing the skin for a brighter and healthier appearance. The products utilize a proven proprietary platform liposome technology that enables the superior effective delivery of Ayurvedic ingredients, antioxidants, moisturizers and vitamins to the outer epidermal and inner dermal layers of skin. As a result, Exquis products provide dramatic positive changes in the health and appearance of skin by reducing the look of uneven skin tone, the appearance of dark spots caused by aging, and repeated environmental exposure, hormonal fluctuations, and even past acne damage.
Exquis founder, Dr. Kale, is an internationally recognized expert in Novel Drug Delivery Technologies with over 20 years of pharmaceutical and cosmeceutical product development experience at some of the world’s leading pharmaceutical companies. Over the course of his career, Dr. Kale has spoken at numerous international conferences and symposiums, and with thousands of people on the topic of skincare. He recognized a common theme in his conversations: that current products are ineffective – they don’t really work. To date, industry’s response has been to “re-fresh”, “re-package” and “re-design” older ineffective solutions in attempts to retain customers’ attention with “new, more effective” products; exploiting people’s continuous search and eagerness to try something new to find a product that actually works.
This recognition has enabled Dr. Kale to fulfill a lifelong passion for founding a company where he could apply his scientific expertise in skin care therapeutics to create truly effective products to help people overcome common skincare issues such as acne, psoriasis, rosacea, eczema and more. His vision for Exquis is to become a branded market leader in the cosmeceutical industry by selling high end beauty and anti-aging products directly to consumers through e-commerce and retail channels such as QVC; and eventually entering the “over the counter” dermatological wellness (“ProActive”) space selling to dermatological practices and spas; and finally the prescription therapeutic Rx medical products space with an expanded product line and/or by licensing his patented liposome technology to competitive, high end brands, effectively becoming the “Intel inside” of skin care products. At present the Company manufactures anti-aging/beauty skincare products sold online through the Company website: www.Exquiseskincare.com.
Technology
Exquis Skincare products are unique and rival the effectiveness of even the most expensive products and technologies on the market now. The advanced, patent-pending, liposome technology utilized in Exquis skincare products provides a vastly superior method of active ingredient delivery. Exquis products contain traditional Ayurvedic ingredients best known for their extensive anti-inflammatory, calming and healing properties, including turmeric, sandalwood, basil, neem and jasmine; and also antioxidants, moisturizers and vitamins. No other skincare product line sold in the USA consists of Ayurvedic Natural Actives delivered through a proprietary liposome technology.
Management
Dr. Kalidas Kale, Founder & CEO: Dr. Kalidas Kale has over 25 years of pharmaceutical R&D experience in the area of novel drug delivery technology, including dermal and transdermal delivery. He obtained a Ph.D. in chemistry from the National Chemical Laboratory in Pune, India and completed his postdoctoral research at Centre des Recherches sur les Macromolecules in Strasbourg, France and Carnegie Mellon University in Pittsburgh PA. He is world-renowned for his contributions and expertise in the field of polymers, colloids and skincare.
Dr. Kale has worked as a principal product development scientist and manager at world-renowned industrial research laboratories including American Cyanamid Company, now Pfizer Inc. (Liposome based drug delivery, parenteral and oral drug delivery), Bristol Myers Squibb Company (Consumer Medicines, Skincare, External technology assessment and New business development) and Barr Laboratories, now TEVA Pharmaceuticals (Management of external projects, Generic drug development). He has received several awards of distinction in recognition for outstanding contributions in developing new products and enabling product launches.
Dr. Kale has also served as an Associate Professor in Pharmaceutics at St. John’s University. At St. John’s, he served as a mentor to talented graduate students and their pursuits in understanding transdermal and liposome delivery. He has also been invited to speak at several international conferences regarding his expertise in the area of novel drug delivery. His accolades include being nominated for a speaking distinction by the organizing committee at the prestigious first International Pharmaceutical Congress in Brazil.
With his numerous patents and research publications, Dr. Kale began searching for something more. Using his knowledge and expertise, he wanted to develop something that could literally change the face of skincare. For over ten years, Dr. Kale began perfecting his formula and has finally developed what is believed to be "the perfect system" for dermal delivery.
Dr. Kale’s vision, blending his leading delivery system with both Natural Ayurvedic and Western world ingredients, gave birth to Exquis- the ultimate in luxury skincare.
Advisors
Harsha Murthy, Advisor
Harsha Murthy is a senior pharmaceuticals and finance executive who has served in numerous leadership positions in the private sector, government and on nonprofit and for-profit boards. Mr. Murthy is currently the Managing Partner of Consummate Capital, LLC, a New York City-based fund that invests in branded and legacy pharmaceutical therapeutic products. Prior to Consummate Capital, Mr. Murthy was founding and managing partner of Konanda Pharma Partners, a New York City-based private equity fund that invested in mature branded pharmaceuticals. Prior to Konanda, Mr. Murthy was Executive Vice President and Corporate Head of Strategic Planning and Business Development for King
Pharmaceuticals, a S&P 500 vertically integrated pharmaceutical company where he led King's M&A, strategic licensing/alliance and divestiture activities.
Before that, Mr. Murthy was an early team member at Eyetech Pharmaceuticals, which was one of the most successful biotech startups in history as it developed a treatment for age-related macular degeneration, the leading cause of blindness in the Western World. Mr. Murthy has also served as a managing director at GE Capital, where he focused on international equity/infrastructure investments in Asia, Africa, South America and the U.S. as well as working with kRoad Ventures, a venture capital fund focused in the energy sector.
Mr. Murthy has served on numerous for-profit boards of directors, including those of Electrolux Corporation, Validus Pharmaceuticals (CNS products), Fontus Pharmaceuticals (rheumatology), MedDEV, Inc. (neuroscience) and TenduTV (digital media company). He has been an advisor to numerous start-up companies in the biotech, pharma, medical device and technology spaces. He is vice-chairman of the board of directors of the Aplastic Anemia and MDS International Foundation (rare bone marrow diseases) and serves in leadership positions on numerous non-profit boards of directors in the arts, civil rights and education/scholarship fields. He is a member of the Duke Angel Investor Network and been an active member of innovation and entrepreneurship groups in New York, Washington, DC and North Carolina.
Mr. Murthy has been a frequent speaker on healthcare and international business issues before industry groups and at academic institutions such as Columbia, Stanford, Harvard, the University of Southern California Business School, Duke, Princeton and the University of Richmond. Mr. Murthy holds degrees from Duke and Stanford.
Patricia Werschulz, Advisor
Ms. Werschulz is an experienced patent and trademark attorney specializing in assistance to small businesses and startups needing help with legal protection for their intellectual property. She has helped clients obtain over 70 patents and 70 trademarks. Prior to her legal career, Ms. Werschulz spent over 30 years as a chemist in the pharmaceutical industry before changing careers, including almost 20 years at Bristol-Meyers Squibb Consumer Medicines Division in manufacturing and R & D. She was a Director in Product Development working closely with marketing, manufacturing and logistics to bring new products from concept stage to store shelf.
Pat is an intellectual property lawyer and a registered patent attorney with many years of industrial experience in product development and manufacturing. Prior to entering law practice, Pat was a chemist in the pharmaceutical industry, holding positions from bench chemist to Research Director. While working in consumer products for a Fortune 100 company, she developed a fascination for trademarks, learning the importance of branding. She chose law, specifically intellectual property law, as a second career because of a long-held fascination with patents and trademarks.
After spending decades in the pharmaceutical industry working with patents, either researching for submission in new patent applications or developing a non-infringing alternate to a competitor’s patent, she wanted to help others file their own applications. As the owner of intellectual property law firm, she provides professional and personal service to inventors, business owners and artists. With an excellent track record of preparing patent and trademark applications and shepherding these applications through the US Patent and Trademark Office, she helps clients protect their valuable ideas. She counsel clients on strategies for building valuable portfolios of intellectual properties both in the US and abroad. Pat’s patent practice has not been limited to just life sciences, but also includes a wide range of industrial consumer products. She has helped clients obtain patents in a wide range of art, from clothing to automobile parts, from baby accessories to sporting equipment.
Ms. Werschulz received her B.S. degree in Chemistry from Chatham College of Pittsburgh, her M.B.A from Fordham University and her J.D from Rutgers School of Law–Newark. Ms. Werschulz has a history of academic excellence, receiving the ABA/BNA Award for Excellence in Intellectual Property Law at Rutgers, the Dean’s Award for Academic Excellence at Fordham, graduating with the highest G.P.A. in her class and the American Chemical Society Outstanding Senior Chemistry Major as an undergraduate.
Louis Masi, Advisor
Dr. Masi is an Executive Vice President (Cofounder and Founding CEO) – of Flo Design Sonics Inc. Previously he was Director, Competitive Intelligence and Technology at Mentor Corporation (Acquired by Ethicon/JnJ), and held positions as a Senior Director, Technology at Inamed Corporation (Acquired by Allergan), and a Unit Manager, Quality Control with Genzyme BioSurgery.
Education: Massachusetts Institute of Technology, Ph.D. Advanced Engineering Fellowship in Applied Sciences
